Browsing by Subject "Transplantasyon"

Now showing 1 - 4 of 4
  • No Thumbnail Available
    Item
    Hepatobilier yetmezlikli-transplantasyon adayı neonatal olgular ve anestezi
    (2008) Verda TOPRAK; Tezcan Gönül KELEŞ; Selçuk BULUT; Tulin Ozturk
    -
  • No Thumbnail Available
    Item
    Çocuklarda aort koarktasyonu tedavisinde balon anjiyoplastinin kısa ve orta dönem sonuçları
    (2008) Talat TAVLI; Türkay SARITAŞ; Faik OKUR; Vedide TAVLI
    Amaç: Çocuk hastalarda aort koarktasyonu için yapılan balon anjiyoplasti uygulamalarının kısa ve orta dönem izlem sonuçları değerlendirildi. Çalışma planı: Çalışmaya, aort koarktasyonu nedeniyle balon anjiyoplasti uygulanan 20 çocuk hasta (12 erkek, 8 kız; ort. yaş 3.4±3.7; dağılım 15 gün-13 yaş) alındı. Olgular, işlem sonrası dönemde sol ventrikül fonksiyonları ve yeniden darlık gelişimi yönünden transtorasik ekokardiyografi ile değerlendirildi. Ortalama izlem süresi 19.6±15.3 ay (dağılım 1-48 ay) idi.Bulgular: Darlığa bağlı tepe sistolik basınç farkı işlem öncesinde ortalama 49.8±14.7 mmHg, işlemin hemen sonrasında 9.3±11.1 mmHg idi (p<0.05). Üç olguda balon anjiyoplasti ile darlık bölgesinde yeterli basınç farkı azalışı sağlanamadı. İzlemde iki olguda geçici alt ekstremite nabız kaybı, bir olguda küçük anevrizma oluşumu görüldü; işlemle ilgili ölüm olmadı. İşlem sonrasında sol ventrikül kütle indeksi ortalamasında istatistiksel olarak anlamlı olmayan %4.3’lük bir azalma belirlendi (p>0.05). Girişim yaşları 11 ve 13 olan iki olguda, işlem başarılı olmasına rağmen hipertansiyon devam etti. Beş olguda ortalama altı ayda yeniden daralma gelişti. Bu olguların dördüne cerrahi rezeksiyon ve uç uca anastomoz, birine de subklavyan flep anjiyoplasti uygulandı. Rezeksiyon ve uç uca anastomoz uygulanan bir olguda ve subklavyan flep anjiyoplasti uygulanan olguda yeniden daralma görüldü ve bu olgulara balon anjiyoplasti planlandı. Sonuç: Aort koarktasyonu tedavisinde balon anjiyoplasti kısa ve orta dönem sonuçları açısından başarılı ve güvenilir bir yöntemdir.
  • No Thumbnail Available
    Item
    Chemotherapy Choice in Neoadjuvant Dual Her2 Blockade: Is it Really Essential to Add Anthracycline?
    (2023) ferhat ekinci; Kutay Kırdök; ATIKE PINAR ERDOGAN; Ahmet Özveren; Elvina Almuradova; Bulent Karabulut
    Objectives: Addition of trastuzumab and pertuzumab to neoadjuvant chemotherapy in Human epidermal growth factor receptor 2 (HER-2) positive breast cancer is the current clinical standard. We aimed to determine whether anthra- cycline-containing neoadjuvant chemotherapy yields beneficial effects alongside dual HER-2 blockade, and to assess cardiotoxicity with this treatment. Methods: Fifty-two patients with HER-2-positive breast cancer who received neoadjuvant chemotherapy were ret- rospectively evaluated at three tertiary health-care centers. The effects of chemotherapy regimen and several other factors such as age, stage, menopause status, lymph node positivity, and hormone receptor positivity on pathological complete response (pCR) were evaluated. Results: The mean age at diagnosis was 46±9 years. The pCR rate was similar between those with and without anthra- cycline-containing regimens (71.4% vs. 70%). Subgroup analyses also showed similar pCR values for those with nega- tive and positive hormone receptors (64.7% vs. 74.3%), those with Ki67 levels <20% and >20% (60% vs. 73.8%), and when premenopausal patients were compared with postmenopausal patients (76.9% vs. 65.4%). Conclusion: It appears that adding anthracycline to dual HER-2 blockade for neoadjuvant therapy did not yield addi- tional benefits in terms of pCR. Further studies are needed to assess anthracycline-containing regimens in patients who will use the neoadjuvant pertuzumab-trastuzumab combination.
  • No Thumbnail Available
    Item
    Clinical characteristics of patients requiring lung transplantation referral in national cystic fibrosis registry data
    (2023) Ayşen Bingöl; ERDEM BAŞARAN; Gökçen Dilşa Tuğcu; Sanem Eryilmaz Polat; Abdulhamit Çollak; Selcuk Uzuner; Nihat Sapan; Zeynep Reyhan Onay; Tugba Ramasli Gursoy; Nural Kiper; Nagehan Emiralioglu; Haluk Cezmi cokugras; Sebnem Ozdogan; Pervin Korkmaz; Sukru Cekic; ZEYNEP ÜLKER TAMAY; Azer Kilic Baskan; Mehmet Alp Kose; Ebru Damadoglu; Tugba Sismanlar Eyuboglu; Ayse Tana Aslan; Gonca KILIÇ; NAZAN ÇOBANOGLU; SEVGI PEKCAN; UĞUR ÖZÇELİK; Deniz Dogru; GUZIN CINEL; Ebru Yalcin; Hadice Selimoğlu Şen; velat ŞEN; Gökçen ünal; Asli imran YILMAZ; Ayse Ayzit Kilinc; Hakan Yazan; Ayse Senay Sasihuseyinoglu; Dilek ÖZCAN; Derya Ufuk Altintas; Gökçen Kartal Öztürk; Esen Demir; Ilim Irmak; Ali Özdemir; koray harmancı; Melih Hangul; Hasan Yuksel; Gizem ÖZCAN; erdem topal; Demet Can; Gönül Çaltepe; Mehmet KILIÇ; Erkan CAKIR
    Background. We aimed to determine the number of cystic fibrosis (CF) patients recorded in the Cystic Fibrosis Registry of Türkiye (CFRT) who were in need of lung transplantation (LT) referral and examine clinical differences between patients who were LT candidates due to rapid forced expiratory volume in one second (FEV₁) decline and LT candidates without rapid FEV₁ decline in the last year to identify a preventable cause in patients with such rapid FEV₁ decline. Methods. All CF patients recorded in the CFRT in 2018 were evaluated in terms of LT. Patients were divided into those with FEV₁ below 50% and in need of LT due to a decrease of 20% or more in the previous year (Group 1) and those who did not have FEV₁ decline of more than 20% in the previous year but had other indications for LT (Group 2). Demographic and clinical features were compared between the two groups. Results. Of 1488 patients registered in CFRT, 58 had a need for LT. Twenty patients were included in Group 1 and others in Group 2. Our findings did not reveal any significant variations in treatment, chronic infection status, or complications between the two groups. The average weight z-score was significantly higher in Group 1. Positive correlations were detected between weight z-score and FEV₁ in 2017 in Group 1 and between FEV₁ values in 2017 and 2018 in Group 2. Conclusions. There appears to be a relationship between the nutritional status and weight z-scores of CF patients and pulmonary function, which may indirectly affect the need for lung transplantation referral.